• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Mumbai , Dec 7

Glenmark Pharmaceuticals, a wholly owned US subsidiary of Glenmark Pharmaceuticals Ltd (India), has signed a supply and marketing agreement with Lehigh Valley Technologies for manufacturing and marketing seven products in the US market.

The products have a cumulative market size of $2.8 billion and belong to the controlled substances category, a company statement said. The products are used for pain management.

The products will be filed with the FDA under Glenmark's name and marketed exclusively by Glenmark in the US. The company expects to launch the products from 2008-09.

"Our second deal with Lehigh will establish our presence in the selling of niche products in the competitive US generics market. We currently market 10 products in the US and expect to end the year with 18-22 generics in the market," said Mr Glenn Saldanha, Managing Director and CEO of Glenmark Pharmaceuticals.

More Stories on : Alliances & Joint Ventures | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Dr Reddy's teams up with Auckland varsity

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line